Skip to main content
TipRanks
Go Ultimate75% OFF

Verastem (VSTM) AI Stock Analysis

2,116 Followers
VSTM

Verastem

(NASDAQ:VSTM)

Select Model
Rating:54Neutral
Price Target:$7.50â–²(9.17% Upside)
Action:reiterated
Date:11/07/26

The score is held back primarily by weak financial performance: large ongoing losses, heavy and worsening cash burn, and a highly levered balance sheet. Offsetting this, the latest earnings call conveyed strong commercial growth and a well-defined clinical/regulatory roadmap with funding runway into 1H 2028. Technically, the setup is mixed (positive longer-term trend vs. weaker near-term momentum), and valuation remains hard to anchor due to negative earnings and no dividend yield data.

Positive Factors
Commercial adoptionRapid product revenue growth, broader physician adoption, and stronger refill activity indicate expanding commercial use and improving treatment persistence. These trends can support a more durable oncology franchise by increasing account penetration and strengthening the base of recurring product demand over coming quarters.
Negative Factors
Persistent cash burnLarge and worsening operating and free cash outflows show that revenue growth has not yet translated into self-funded operations. Continued cash consumption increases reliance on financing and leaves less flexibility if clinical spending rises, commercial growth slows, or development timelines extend.

Verastem (VSTM) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%VSTM-30.18%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$865.72M
Dividend Yield
―
Average Volume (3M)
3.47M
Price to Earnings (P/E)
-3.7
Beta (1Y)
1.16
Revenue Growth
649.65%
EPS Growth
54.01%
Country
US
Employees
102
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Verastem Business Overview & Revenue Model

Company Description

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by...

Verastem Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-26.76%|Next Earnings Date:Mar 18, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported 114% year-over-year product revenue growth, increasing refill momentum, a strengthened balance sheet with funding into the first half of 2028, encouraging VS-7375 efficacy across pancreatic, colorectal and lung cancers, favorable safety data, and multiple advancing Phase II and Phase III programs. The main negatives were moderated new patient starts, anticipated competitive pressure in pancreatic cancer, a larger adjusted net loss, and remaining clinical, regulatory and site-enrollment execution requirements.

Positive Updates

Strong Third-Quarter Product Revenue Growth
Net product revenue from AVMAPKI FAKZYNJA CO-PACK was $24.0 million in the third quarter of 2026, a 114% increase compared with the third quarter of 2025. Revenue was supported by expanded prescribing across community and academic accounts, increasing refill rates, and strong refills offsetting new patient starts after significant growth in the second quarter.

Negative Updates

Moderation in New Patient Starts
New patient starts moderated in the third quarter after significant overall growth in the second quarter. Management attributed this to seasonal headwinds in the late summer and noted that new patient starts can fluctuate quarter-to-quarter because treatment persistence in rare diseases such as LGSOC is episodic.

Company Guidance

Verastem expects SG&A expenses will remain consistent on a quarterly basis in the fourth quarter of 2026, with current cash, October follow-on offering proceeds and expected AVMAPKI FAKZYNJA CO-PACK revenues funding operations into the first half of 2028, including completing VS-7375 Phase II studies and starting 3 pivotal Phase III studies; pancreatic and colorectal Phase II enrollment is expected to complete around the end of the year and lung enrollment in the first half of 2027, the frontline Phase III TARGET-D 301 PDAC trial is expected to initiate before the end of 2026, and the frontline Phase III TARGET-D trials in CRC and non-small cell lung cancer are planned for the first half of 2027. The company expects an update across the program at the first of the year, multiple updates across the program in the next couple of months, the blister pack to launch in the first half of next year, 7375 plus gem/nab data in Q1 or Early Q2, and typically these Phase IIIs are 100 sites.

Verastem Financial Statement Overview

Summary

Revenue is scaling rapidly (TTM ~$100.3M vs. $30.9M in 2025), but profitability and cash generation remain very weak (TTM net income about -$178.9M; operating cash flow about -$159.6M; free cash flow about -$160.9M). Balance-sheet risk is elevated given sharply higher leverage (TTM debt ~$122.1M vs. equity ~$10.1M; ~12.1x debt-to-equity), implying continued funding pressure despite the revenue ramp.

Income Statement

22Negative

Balance Sheet

28Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue100.30M30.91M10.00M02.60M2.05M
Gross Profit86.37M25.62M10.00M02.60M2.05M
EBITDA-175.58M-207.60M-125.86M-83.17M-71.56M-61.16M
Net Income-178.90M-209.47M-130.64M-87.37M-73.81M-71.20M
Balance Sheet
Total Assets229.64M246.44M101.54M149.72M95.05M108.66M
Cash, Cash Equivalents and Short-Term Investments172.80M204.99M88.82M137.13M87.89M100.26M
Total Debt122.12M76.86M42.25M41.56M27.07M3.18M
Total Liabilities219.54M189.25M130.43M92.34M47.66M21.10M
Stockholders Equity10.10M57.20M-28.89M57.37M47.39M87.56M
Cash Flow
Free Cash Flow-160.92M-137.51M-104.80M-86.46M-63.67M-53.70M
Operating Cash Flow-159.57M-137.51M-104.77M-86.46M-63.67M-53.50M
Investing Cash Flow-8.61M-9.62M59.97M-44.45M66.19M87.00K
Financing Cash Flow203.28M263.31M54.78M134.19M51.78M6.88M

Verastem Technical Analysis

Technical Analysis SentimentNegative
Last Price6.87

Price Trends

50DMA8.44Negative
100DMA7.39Negative
200DMA6.31Positive

Market Momentum

MACD-0.30Positive
RSI31.19Neutral
STOCH2.17Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSTM, the sentiment is Negative. The current price of 6.87 is below the 20-day moving average (MA) of 9.08, below the 50-day MA of 8.44, and above the 200-day MA of 6.31, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 31.19 is Neutral, neither overbought nor oversold. The STOCH value of 2.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSTM.

Verastem Risk Analysis

Verastem disclosed 67 risk factors in its most recent earnings report. Verastem reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Item 3. Defaults Upon Senior Securities.Q3, 2024
2.Item 5. Other Information.Q3, 2024
3.Item 4. Mine Safety Disclosures.Q3, 2024

Verastem Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

VSTM against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PBYIPBYI61Neutral$369.13M15.1617.52%―9.35%-37.15%
VSTMVSTM54Neutral$865.72M-3.71-359.49%―649.65%54.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARVNARVN49Neutral$443.01M-45.10-2.00%―-11.85%81.44%
CTMXCTMX46Neutral$409.85M-4.17-33.97%―-87.66%-210.45%
ALLOALLO40Underperform$241.11M-1.10-49.84%――36.37%
BBOTBBOT37Underperform$144.85M-0.00-49.01%――-132725.78%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%VSTMPBYICTMXARVNALLOBBOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
VSTM and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
VSTMVerastem Inc6.87-3.13-31.30%
PBYIPuma Biotechnology7.222.3347.65%
CTMXCytomX Therapeutics Inc.1.88-2.00-51.55%
ARVNArvinas Holding Company6.76-4.75-41.28%
ALLOAllogene Therapeutics0.69-0.54-43.50%
BBOTBridgebio Oncology Therapeutics, Inc.1.80-10.59-85.43%

Verastem Corporate Events

Business Operations and Strategy

Verastem Updates Corporate Presentation on Oncology Programs

Neutral
Nov 5, 2026

On November 5, 2026, Verastem posted an updated corporate presentation on its website. The presentation covered the company’s oncology programs and product candidates, including AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules and defactinib tablets)...

Business Operations and StrategyPrivate Placements and Financing

Verastem Announces $234 Million Oncology Financing Transaction

Positive
Oct 14, 2026

On October 14, 2026, Verastem entered into an underwriting agreement with Jefferies and Guggenheim Securities for an underwritten public offering of 30,937,500 shares of common stock and pre-funded warrants to purchase up to 312,503 additional shares...

Business Operations and StrategyExecutive/Board ChangesProduct-Related AnnouncementsRegulatory Filings and Compliance

Verastem Oncology Announces CEO Transition to Michael Bailey

Positive
Oct 14, 2026

Verastem Oncology said on October 14, 2026, that longtime executive Daniel Paterson will retire as president and CEO effective January 1, 2027, while remaining on the board and serving as an advisor, with board member and veteran oncology executive M...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026